Age-Related Macular Degeneration

Although the use of β-Blockers did not affect early-stage AMD, their long-term use was indicated to be protective against the risk of AMD among patients with hypertension.

A new study indicates that OCTA-derived features of MNV disease activity may be useful biomarkers to confirm MNV stability in patients with treated stable nAMD.

The therapy is the first and only FDA-approved treatment for geographic atrophy, with approval based on positive results from the phase 3 DERBY and OAKS trials.

The NDA has been granted Priority Review with a PDUFA goal date of August 19, 2023. The FDA is not currently planning to hold an Advisory Committee meeting.

A new analysis cautions against the use of the Amsler grid test, suggesting its performance is not at a level recommended for monitoring in a patient population with an a priori risk of nAMD.

Cross-sectional results from the population-based AugUR study suggest a highly significant association between prolonged PRT with early and late AMD.

The significant association between dietary calcium consumption and AMD risk indicates the need for further evaluation of dietary mineral elements in older adults in the US.

A meta-analysis and systematic review of RCTs saw no difference between face-down positioning and non-face-down positioning with regard to full-thickness macular hole closure.

A multivariate linear mixed model regression analysis of eyes without DR indicates no statistically significant differences in retinal venular or arteriolar width between subtypes and patients with classical T2D.

A post-hoc analysis of the XIRIUS and XOLARIS trials suggest the gene therapy improved some visual function for patients with XLRP, but the reported SAEs require further safety assessments.

Based on the findings, investigators suggest the evaluation of diastolic blood pressure be considered as a therapeutic measure in patients with glaucoma.

An analysis of Denmark's FORSYN study suggests new advances in the treatment of chorioretinal vascular diseases have significantly reduced vision loss.

Data indicate 2 out of 5 patients utilized LVR services among those who received a referral recommendation during the CDSS active phase, while onsite LVR service provision increased utilization rates.

An analysis of the Lifelines cohort revealed DED had a significant impact on work functioning, comparable to the impact of other chronic diseases considered function impairing.

Phase 2b findings suggest VEGF-C/D inhibition with 2.0 mg OPT-302 in combination with ranibizumab achieves superior vision gains compared to the current standard of care for nAMD.

The January 2023 ophthalmology month in review features modifications in age-related macular degeneration risk, links between ophthalmic disease and quality of life, and complications during cataract surgery.

Real-world data suggest nAMD eyes can extend injection intervals by switching to brolucizumab from other anti-VEGF therapies, while maintaining vision and reducing CMT.

Repeated injections with preoperative povidone-iodine application was associated with reduced meibomian gland loss, increased tear volume, and reduced signs of inflammation.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

The phase 3 GOBI study endpoints was significantly greater with NOV03 versus hypotonic saline on the change from baseline at Week 8.

The retrospective study reported the presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi therapy failure.

The lowest mean utility value was observed in the most severe disease state of constant diplopia and large proptosis.

The data from the DPPOS cohort report no difference in AMD presence or severity between metformin, intensive lifestyle intervention, and placebo arms.

Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects.